Our exploratory study evaluated Amp11q13 as a potential predictive biomarker to inform first-line treatment decisions regarding anti-PD-1 therapy in patients with R/M HNSCC. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.